Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bioanalytical services. The company specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. The company focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identified up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
Follow-Up Questions
PIQLF 주식의 가격 성능은 어떻습니까?
PIQLF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Proteomics International Laboratories Ltd의 주요 사업 주제나 업종은 무엇입니까?
Proteomics International Laboratories Ltd은 Life Sciences Tools & Services 업종에 속하며, 해당 부문은 Health Care입니다
Proteomics International Laboratories Ltd의 시가총액은 얼마입니까?
Proteomics International Laboratories Ltd의 현재 시가총액은 $0입니다
Proteomics International Laboratories Ltd는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Proteomics International Laboratories Ltd에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 0명의 매수, 3명의 보유, 3명의 매도, 그리고 0명의 강력한 매도를 포함합니다
